Financial results for the period ended Jun 30, 2026
As filed · Alembic Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
What happened
FactAlembic Pharmaceuticals Limited's Board of Directors approved the Consolidated and Standalone Unaudited Financial Results for the quarter ended 30th June, 2026, during a meeting held on 4th August, 2026. The meeting commenced at 12:00 noon and concluded at 1:55 p.m. The Limited Review Report issued by the Statutory Auditors was also included in the approval.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Debt
Withdrawngross debt was about -- we are at around INR1,600 crores of gross debt.
we should see this debt levels moderating.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- I think about 15-odd percent or so of what I've guided for that the business will grow, and I think we're quit (management committed by FY27)
- Expenditures on artificial intelligence within the healthcare sector are anticipated to attain a value of US$ (management committed by FY30)
Evidence
- Alembic Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 04, 2026.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%